Danazol in autoimmune haemolytic anaemia

Jean‐Michel Pignon, Emmanuelle Poirson, H Rochant
In: British Journal of Haematology · 1993 · vol. 83(2) , pp. 343–345 · doi:10.1111/j.1365-2141.1993.tb08293.x · PMID:8457484 · W2131010849
article OA: closed CC0 ⤵ 7 in-corpus citations
View on OpenAlex View on PubMed View at publisher

Abstract

Ten adult patients with warm antibody haemolytic anaemia at initial presentation and seven other patients with either refractory AIHA (two patients) or who relapsed after an initial response to prednisone (five patients) were treated with both Danazol and prednisone. 80% of the first group, but also 60% of the second group displayed long-lasting responses (mean follow up 21 months). Minimal side-effects occurred. Finally, addition of Danazol at presentation in warm AIHA may decrease the duration of prednisone therapy and markedly reduce the necessity of second-line splenectomy which is usually required in many patients.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (10)

Cited by (7)

Source provenance

openalex
last seen: 2026-05-11T05:49:40.447239+00:00
License: CC0 · commercial use OK